Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1 | Q15116 | 1/20 | 0.44 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.42 |
| ▸ | HRH2 | P25021 | 2/20 | 0.42 |
| ▸ | HRH1 | P35367 | 2/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20165265 | 1.00 | PDCD1 (0.44) | PDCD1CD274HRH3HRH2HRH1 | |
| SCHEMBL20165361 | 1.00 | PDCD1 (0.44) | PDCD1CD274HRH3HRH2HRH1 | |
| SCHEMBL6404065 | 0.87 | — | — | |
| SCHEMBL8759152 | 0.87 | — | — | |
| SCHEMBL2893257 | 0.87 | — | — | |
| SCHEMBL28960041 | 0.87 | PDCD1 (0.49) | PDCD1CD274HRH3HRH2HRH1 | |
| SCHEMBL2674136 | 0.83 | PDCD1 (0.44) | PDCD1CD274HRH3HRH2HRH1 | |
| SCHEMBL12279922 | 0.83 | PDCD1 (0.44) | PDCD1CD274HRH3HRH2HRH1 | |
| SCHEMBL12280022 | 0.83 | PDCD1 (0.44) | PDCD1CD274HRH3HRH2HRH1 | |
| SCHEMBL25730152 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116744920-A | Heteroaryl piperidine derivative, and pharmaceutical composition and application thereof | 贝达药业股份有限公司 | 2023-09-12 | — | — | CN | claimed |
| WO-2022166983-A1 | HETEROARYLOPIPERIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 贝达药业股份有限公司 | 2022-08-11 | — | — | WO | claimed |
| US-20250262186-A1 | NOVEL SUBSTITUTED FLUORINATED N-PROPYL-PYRROLIDINE AND N-PROPYL-AZETIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2025-08-21 | — | — | US | disclosed |
| EP-4577531-A1 | NOVEL SUBSTITUTED 2-CARBONYL-BENZOTHIOPHENE-6- CARBOXYLIC ACID DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | Sanofi (FR) | 2025-07-02 | — | — | EP | disclosed |
| EP-4577534-A1 | NOVEL SUBSTITUTED TETRAHYDROISOQUINOLINE-6- CARBOXYLIC ACID DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | Sanofi (FR) | 2025-07-02 | — | — | EP | disclosed |
| EP-3541809-B1 | NOVEL SUBSTITUTED N-(3-FLUOROPROPYL)-PYRROLIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | SANOFI SA (FR) | 2025-06-25 | — | — | EP | disclosed |
| EP-4508033-A1 | NOVEL SUBSTITUTED FLUORINATED N-PROPYL-PYRROLIDINE AND N-PROPYL-AZETIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | Sanofi (FR) | 2025-02-19 | — | — | EP | disclosed |
| US-11999728-B2 | Estrogen receptor modulators | RECURIUM IP HOLDINGS, LLC (US) | 2024-06-04 | — | — | US | disclosed |
| WO-2024042185-A1 | NOVEL SUBSTITUTED TETRAHYDROISOQUINOLINE-6- CARBOXYLIC ACID DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF. | SANOFI (FR) | 2024-02-29 | — | — | WO | disclosed |
| WO-2024042152-A1 | NOVEL SUBSTITUTED 2-CARBONYL-BENZOTHIOPHENE-6- CARBOXYLIC ACID DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2024-02-29 | — | — | WO | disclosed |
| WO-2024042163-A1 | NOVEL SUBSTITUTED 2,3,4,9-TETRAHYDRO-1H-PYRIDO[3,4-B]INDOLE CARBOXYLIC ACID DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2024-02-29 | — | — | WO | disclosed |
| WO-2022140744-A1 | ESTROGEN RECEPTOR MODULATORS | RECURIUM IP HOLDINGS, LLC (US) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022140744-A1 | ESTROGEN RECEPTOR MODULATORS | RECURIUM IP HOLDINGS, LLC (US) | 2022-06-30 | — | — | WO | disclosed |
| US-11339162-B1 | Estrogen receptor modulators | RECURIUM IP HOLDINGS, LLC (US) | 2022-05-24 | — | — | US | disclosed |
| US-11339162-B1 | Estrogen receptor modulators | RECURIUM IP HOLDINGS, LLC (US) | 2022-05-24 | — | — | US | disclosed |
| US-11149031-B2 | Substituted N-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof | SANOFI (FR) | 2021-10-19 | — | — | US | disclosed |
| US-20200361918-A1 | NOVEL SUBSTITUTED N-(3-FLUOROPROPYL)-PYRROLIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT (FR) | 2020-11-19 | — | — | US | disclosed |
| EP-3541809-A1 | NOVEL SUBSTITUTED N-(3-FLUOROPROPYL)-PYRROLIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | Sanofi (FR) | 2019-09-25 | — | — | EP | disclosed |
| WO-2018091153-A1 | NOVEL SUBSTITUTED N-(3-FLUOROPROPYL)-PYRROLIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2018-05-24 | — | — | WO | disclosed |
| WO-2018091153-A1 | NOVEL SUBSTITUTED N-(3-FLUOROPROPYL)-PYRROLIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361918-A1 | NOVEL SUBSTITUTED N-(3-FLUOROPROPYL)-PYRROLIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | ESR1, CYP19A1, ESR2 | PDCD1 3643/4885CD274 3855/4885HRH3 1505/4885 |
| US-11149031-B2 | Substituted N-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof | ESR1, CYP19A1, ESR2 | PDCD1 3785/4885CD274 3999/4885HRH3 1256/4885 |
| US-11339162-B1 | Estrogen receptor modulators | ESR2, GPER1, ESRRA | PDCD1 4579/4885CD274 4091/4885HRH3 3585/4885 |
| US-11999728-B2 | Estrogen receptor modulators | ESR2, GPER1, ESRRA | PDCD1 4579/4885CD274 4091/4885HRH3 3585/4885 |
| US-20250262186-A1 | NOVEL SUBSTITUTED FLUORINATED N-PROPYL-PYRROLIDINE AND N-PROPYL-AZETIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | FSHR, CYP19A1, GPER1 | PDCD1 3356/4885CD274 3635/4885HRH3 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.